ADG106 + Doxorubicin + Cyclophosphamide + Paclitaxel

Phase 1/2Active

1 views this week 0 watching💤 Quiet

Interest: 26/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

HER2-negative Breast Cancer

Conditions

HER2-negative Breast Cancer, Advanced Solid Tumor

Trial Timeline

May 19, 2022 → Feb 1, 2030

NCT ID

NCT05275777

About ADG106 + Doxorubicin + Cyclophosphamide + Paclitaxel

ADG106 + Doxorubicin + Cyclophosphamide + Paclitaxel is a phase 1/2 stage product being developed by Adagene for HER2-negative Breast Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT05275777. Target conditions include HER2-negative Breast Cancer, Advanced Solid Tumor.

What happened to similar drugs?

1 of 8 similar drugs in HER2-negative Breast Cancer were approved

Approved (1) Terminated (0) Active (7)

🔄E7389 (Eribulin Mesylate) + Vinorelbine injectionEisaiPhase 3

🔄Fluzoparib; Apatinib + Fluzoparib + Physician's choice chemotherapyJiangsu Hengrui MedicinePhase 3

🔄AZD9833 + AZD9833 Placebo + Anastrozole + Anastrozole placebo + Letrozole + Letrozole placebo + Palbociclib + Abemaciclib + Luteinizing hormone-releasing hormone (LHRH) agonist + RibociclibAstraZenecaPhase 3

🔄AZD9833 + Anastrozole + Anastrozole placebo + AZD9833 placebo + Palbociclib + Luteinizing hormone-releasing hormone (LHRH) agonistAstraZenecaPhase 3

✅Zoledronic acid + Standard TherapyNovartisApproved

🔄Giredestrant + Giredestrant-matched Placebo + Letrozole + Letrozole-matched Placebo + Palbociclib + LHRH AgonistRochePhase 3

🔄Giredestrant + Fulvestrant + Abemaciclib + Palbociclib + Ribociclib + LHRH AgonistRochePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05275777	Phase 1/2	Active	May 19, 2022	Feb 1, 2030	HER2-negative Breast Cancer

Competing Products

19 competing products in HER2-negative Breast Cancer

See all competitors

Product	Company	Stage	Hype Score
E7389 (Eribulin Mesylate) + Vinorelbine injection	Eisai	Phase 3	40
Durvalumab + Eribulin	Eisai	Phase 1	29
Fluzoparib; Apatinib + Fluzoparib + Physician's choice chemotherapy	Jiangsu Hengrui Medicine	Phase 3	36
AZD9833 + AZD9833 Placebo + Anastrozole + Anastrozole placebo + Letrozole + Letrozole placebo + Palbociclib + Abemaciclib + Luteinizing hormone-releasing hormone (LHRH) agonist + Ribociclib	AstraZeneca	Phase 3	44
AZD9833 + Anastrozole + Anastrozole placebo + AZD9833 placebo + Palbociclib + Luteinizing hormone-releasing hormone (LHRH) agonist	AstraZeneca	Phase 3	44
[14C]AZD9833 Oral Solution, 75 mg	AstraZeneca	Phase 1	29
AZD9833 + Fulvestrant	AstraZeneca	Phase 2	39
AZD9833	AstraZeneca	Phase 2	35
Pembrolizumab	Merck	Phase 2	39
Vinorebine, Everolimus + Vinorelbine	Novartis	Phase 2	35
L-NMMA	Novartis	Phase 2	42
Zoledronic acid + Standard Therapy	Novartis	Approved	43
LEE011 + Letrozole + Tamoxifen + Fulvestrant + goserelin	Novartis	Phase 1	29
Giredestrant + Giredestrant-matched Placebo + Letrozole + Letrozole-matched Placebo + Palbociclib + LHRH Agonist	Roche	Phase 3	44
Giredestrant + Fulvestrant or an Aromatase Inhibitor (Physician Choice) + LHRH Agonist	Roche	Phase 2	39
Giredestrant + Fulvestrant + Abemaciclib + Palbociclib + Ribociclib + LHRH Agonist	Roche	Phase 3	47
Capecitabine + Carboplatin + Cisplatin + Sacituzumab govitecan	Gilead Sciences	Phase 3	44
Non-Investigational Antibody-Drug Conjugates (ADC)	Gilead Sciences	Pre-clinical	33
PLD Chemotherapy + CDX-1140 + CDX-301	Celldex Therapeutics	Phase 1	30